Compounds and methods for treating gastrointestinal disease
AssigneeThe Regents of the University of California
InventorWael N. El-Nachef
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such compounds and related pharmaceutical compositions may be used for targeted treatment of diabetic and non-diabetic gastrointestinal disorders, with minimal systemic circulation beyond the gastrointestinal tract.
Claims51
A compound, comprising a pharmacophore and a targeting moiety, wherein the targeting moiety causes the pharmacophore to undergo first pass metabolism.
A chemical moiety, wherein, when the moiety is covalently bonded to a pharmacophore, the moiety causes the pharmacophore to undergo first pass metabolism.
Dependencies are inferred from the claim text.